About Enliven Therapeutics
Enliven Therapeutics (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help cancer patients live longer and better. The company applies a precision oncology approach, combining deep insights from clinically validated biological targets with differentiated chemistry to design potentially first-in-class or best-in-class therapies. Its pipeline includes ELVN-001, a BCR-ABL inhibitor for chronic myeloid leukemia, and ELVN-002, a HER2 inhibitor for solid tumors.
Company details
Funding
Total raised
$140M
Last stage
Public
Investors
Founders
Joe Lyssikatos
Co-founder and CSO of Enliven Therapeutics. Previously Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma. Earned a PhD in Chemistry from UC Berkeley.
Anish Patel
Co-founder and COO of Enliven Therapeutics. Holds a PharmD degree. Co-founded the company in July 2019 alongside Sam Kintz and Joe Lyssikatos.
Sam Kintz
Co-founder of Enliven Therapeutics; previously Executive Director of Research at AbbVie and Head of Research at AbbVie Stemcentrx. Also worked at Roche Venture Fund and as a medicinal chemist at Genentech. Holds an MBA and BS in Chemistry from Stanford University.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.